Archive · 26 Aug 2026
Lupin Reassesses GLP-1 Market as It Develops New Treatments
Lupin makes medicines for diabetes and other health conditions.
It says medicines called GLP-1 drugs will still be important for its business.
However, Lupin now thinks the overall market may not become as large as it first expected.
The company is preparing several different treatments instead of relying only on semaglutide.
One possible medicine, bofenglutide, could be taken once every two weeks.
Lupin is also developing an oral version of semaglutide.
It wants to sell semaglutide in countries such as South Africa, Canada and Brazil.
More companies are developing competing drugs and combinations called GLP-1/GIP treatments.
Lupin is also helping patients learn how to use the medicines and stay on treatment.
Lupin says the GLP-1 market may be smaller than initially expected but remains important to its business.
The company is developing bofenglutide, a potential long-acting treatment designed for administration once every two weeks.
Lupin plans to expand semaglutide beyond India, initially considering South Africa and later Canada and Brazil.
The company is developing oral semaglutide and preparing for competition from newer products and GLP-1/GIP combinations.
Lupin is supporting patients through its Humrahi programme and has partnerships with Zydus Lifesciences and Gan & Lee.
- Who
- Lupin, including Rajeev Sibal and an unnamed company spokesperson identified as Swaminathan.
- What
- Lupin is reassessing the size of the GLP-1 market while expanding its portfolio of semaglutide, bofenglutide and oral treatments.
- When
- The company discussed the outlook during its June-quarter update; no year was specified.
- Where
- Lupin’s current semaglutide business is in India, with potential expansion to South Africa, Canada and Brazil.
- Why
- The company expects increasing competition, newer products and GLP-1/GIP combinations, while its initial assessment suggests the market may be smaller than expected.
- Market outlook
- Lupin says initial reactions suggest the GLP-1 market may be smaller than it first expected.
- Key treatment
- The company expects GLP-1 medicines to remain an important part of its business.
- Bofenglutide
- Lupin is developing bofenglutide as a long-acting treatment intended for once-every-two-weeks administration.
- Expansion markets
- Lupin is considering South Africa and, over time, Canada and Brazil for its semaglutide business.
- Oral programme
- The company is developing an in-house oral semaglutide programme.
- Partnerships
- Lupin has agreements with Zydus Lifesciences for semaglutide in India and with Gan & Lee for bofenglutide.
- Patient support
- Its Humrahi programme offers counselling, onboarding, injection training and adherence support.